Bishara, Andrew http://orcid.org/0000-0002-5427-482X
Wong, Andrew
Wang, Linshanshan
Chopra, Manu
Fan, Wudi
Lin, Alan
Fong, Nicholas
Palacharla, Aditya
Spinner, Jon
Armstrong, Rachelle
Pletcher, Mark J.
Lituiev, Dmytro
Hadley, Dexter
Butte, Atul
Funding for this research was provided by:
National Institutes of Health (T32 NIH funding 5T32GM008440, PI: Judith Hellman)
Article History
Received: 29 December 2020
Accepted: 21 October 2021
First Online: 27 November 2021
Declarations
:
: Andrew Bishara is a co-founder of Bezel Health, a company building software to measure and improve healthcare quality interventions. Atul Butte is a co-founder and consultant to Personalis and NuMedii; consultant to Samsung, Mango Tree Corporation, and in the recent past, 10 × Genomics, Helix, Pathway Genomics, and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, and Merck, and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Facebook, Google, Microsoft, Sarepta, Moderna, Regeneron, 10 × Genomics, Amazon, Biogen, CVS, Illumina, Snap, Nuna Health, Assay Depot, Vet24seven, and Sutro, and several other non-health related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Genentech, Takeda, Varian, Roche, Pfizer, Merck, Lilly, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Johnson and Johnson, Westat, and many academic institutions, medical or disease specific foundations and associations, and health systems. Atul Butte receives royalty payments through Stanford University, for several patents and other disclosures licensed to NuMedii and Personalis. Atul Butte’s research has been funded by NIH, Robert Wood Johnson Foundation, Northrup Grumman (as the prime on an NIH contract), Genentech, Johnson and Johnson, FDA, the Leon Lowenstein Foundation, the Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governor’s Office of Planning and Research, California Institute for Regenerative Medicine, L’Oreal, and Progenity. None of these above-mentioned competing interests relate to Opal or to this manuscript.
: Data retrieval was approved by the UCSF institutional review board (IRB #17–23204) from UCSF’s EHR data warehouse for all operative cases from 2012 onward and the requirement for informed consent was waived by the IRB.
: Not applicable for this research.